Development of a prognostic model for lung adenocarcinoma polarity-related genes and analysis of immune landscape

被引:0
作者
Xu, Hongqiu [1 ]
Du, Wenqiang [1 ]
Jing, Xuelong [1 ]
Xie, Jingen [1 ]
Li, Pengfei [1 ,2 ]
机构
[1] Huaian Hosp Huaian City, Dept Gen Med, Huaian, Jiangsu, Peoples R China
[2] Huaian Hosp Huaian City, Dept Gen Med, 19 Shanyang Ave, Huaian 223200, Jiangsu, Peoples R China
关键词
cell polarity; immune; lung adenocarcinoma; prognostic model; TMB; OSTEOARTHRITIS; BIOSENSOR;
D O I
10.1002/bab.2579
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Despite the progress made in the management of lung adenocarcinoma (LUAD), the overall prognosis for LUAD individuals remains suboptimal. While the role of cell polarity in tumor invasion and metastasis is well established, its prognostic significance in LUAD is still unknown. Differential analysis was performed on the Cancer Genome Atlas (TCGA)-LUAD and normal lung tissue, and candidate genes were identified by intersecting differentially expressed genes with polarity-related genes (PRGs). A prognostic model was constructed using univariate and multivariate Cox regression and LASSO regression. To enhance the robustness of the analysis, an independent prognostic analysis was conducted by incorporating relevant clinical information. The accuracy and sensitivity of the model were validated using survival analysis and ROC curves. Finally, immune landscape, immune therapy, tumor mutation burden, and drug sensitivity analysis were carried out on high- and low-risk patients. Ten prognostic genes were screened to divide LUAD patients into different risk groups. Survival analysis, ROC curves, and univariate/multivariate Cox regression analyses collectively demonstrated the favorable predictive performance of the model, which could be an independent prognostic factor. The nomogram, in conjunction with the calibration curve, demonstrated the model's compelling predictive capacity in prognosticating the overall survival of LUAD individuals. Low-risk LUAD patients exhibited heightened levels of immune cell infiltration, immune scores, and immune checkpoint expression compared to high-risk individuals. So, they may have a greater likelihood of benefiting from immune therapy. The high-risk group demonstrated a remarkably higher tumor mutation burden (TMB) in contrast with the low-risk group. XAV-939, Fulvestrant, and SR16157 may have potential value in the clinical use of LUAD. We revealed the potential linkage between PRGs and LUAD prognosis, and the application of these prognostic factors in risk stratification and prognosis prediction of LUAD patients may be of great significance.
引用
收藏
页码:817 / 834
页数:18
相关论文
共 68 条
  • [1] Anumanthan A, 1998, J IMMUNOL, V161, P2780
  • [2] Gene Ontology: tool for the unification of biology
    Ashburner, M
    Ball, CA
    Blake, JA
    Botstein, D
    Butler, H
    Cherry, JM
    Davis, AP
    Dolinski, K
    Dwight, SS
    Eppig, JT
    Harris, MA
    Hill, DP
    Issel-Tarver, L
    Kasarskis, A
    Lewis, S
    Matese, JC
    Richardson, JE
    Ringwald, M
    Rubin, GM
    Sherlock, G
    [J]. NATURE GENETICS, 2000, 25 (01) : 25 - 29
  • [3] Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe
    Asl, Elmira Roshani
    Rostamzadeh, Davoud
    Duijf, Pascal H. G.
    Mafi, Sahar
    Mansoori, Behnaz
    Barati, Shirin
    Cho, William C.
    Mansoori, Behzad
    [J]. LIFE SCIENCES, 2023, 315
  • [4] Preparation of chitosan nanoparticles for simultaneous drug delivery of dacarbazine and enoxaparin in melanoma
    Ataabadi, Fahimeh Vahidi
    Oveissi, Farnoush
    Etebari, Mahmoud
    Taheri, Azade
    [J]. CARBOHYDRATE POLYMERS, 2023, 316
  • [5] The tumor microenvironment at a glance
    Balkwill, Frances R.
    Capasso, Melania
    Hagemann, Thorsten
    [J]. JOURNAL OF CELL SCIENCE, 2012, 125 (23) : 5591 - 5596
  • [6] CD4+ T helper 2 cells suppress breast cancer by inducing terminal differentiation
    Boieri, Margherita
    Malishkevich, Anna
    Guennoun, Ranya
    Marchese, Emanuela
    Kroon, Sanne
    Trerice, Kathryn E. E.
    Awad, Mary
    Park, Jong Ho
    Iyer, Sowmya
    Kreuzer, Johannes
    Haas, Wilhelm
    Rivera, Miguel N. N.
    Demehri, Shadmehr
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2022, 219 (07)
  • [7] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [8] The Role of Macrophages in Cancer Development and Therapy
    Cendrowicz, Ewa
    Sas, Zuzanna
    Bremer, Edwin
    Rygiel, Tomasz P.
    [J]. CANCERS, 2021, 13 (08)
  • [9] Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
    Charoentong, Pornpimol
    Finotello, Francesca
    Angelova, Mihaela
    Mayer, Clemens
    Efremova, Mirjana
    Rieder, Dietmar
    Hackl, Hubert
    Trajanoski, Zlatko
    [J]. CELL REPORTS, 2017, 18 (01): : 248 - 262
  • [10] DCBLD2 Mediates Epithelial-Mesenchymal Transition-Induced Metastasis by Cisplatin in Lung Adenocarcinoma
    Chen, Xiaosu
    Lv, Yajing
    Xu, Kejia
    Wang, Xiaoshuang
    Zhao, Yujia
    Li, Jia
    Qin, Xuan
    Shi, Yi
    Wang, Longlong
    Chang, Antao
    Huang, Chongbiao
    Xiang, Rong
    [J]. CANCERS, 2021, 13 (06) : 1 - 27